HomeQuestion

Would you consider SBRT for fibrolamellar HCC that is inoperable?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?

In patients with unresectable, liver-limited neuroendocrine tumors (NETs), what clinical or radiographic criteria guide your decision to prioritize systemic therapy over locoregional approaches?

In a patient with pancreatic cancer who is heterozygous for the ATM c.875C>T (Pro292Leu) mutation with functional impairment in the gene product, is there any data or recommendation to support using SBRT vs. chemo-RT?

What adjuvant treatment approach would you recommend for a patient with early-stage MSI-high gastric cancer who received neoadjuvant ipilimumab (×2) and nivolumab (×6) per the NEONIPIGA regimen, followed by R0 resection with no pathologic response?

What are your top takeaways from ASCO GI 2026?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.

Would you consider SBRT for fibrolamellar HCC that is inoperable? | Mednet